Collaborative InnovationThe role of the Academy and the Pharma IndustryJoining our Efforts, Sharing our Future            ...
Outline          A Global Collaborative          Environment          Collaborative Innovation @          Ferrer          ...
A Global EnvironmentTrends in Biopharma Industry. The future has arrived.                                                 ...
A Global EnvironmentWhat to do...                                                      To increase Corporate efficiency:  ...
A Global Environment  And M&A arrived...             PHARMACIA                                  PFIZER INC. UPJOHN        ...
A Global Environment     SANOFI                                        RHONE-POULENC R                   STERLING W       ...
A Global EnvironmentFocus on reducing generic-induced erosion of revenues...                                              ...
A Global EnvironmentBut… are M&A solving the problem?What about the announced synergies?                                  ...
A Global EnvironmentWhat to do...                                                      To increase Corporate efficiency:  ...
A Global Collaborative Environment In 1996…                                                Jürgen Drews                   ...
A Global Collaborative Environment  1975      1985         1995           2005               2015   CLIN      CLIN        ...
A Global Collaborative Environment   1975         1985          1995           2005               2015…   CLIN          CL...
A Global Collaborative EnvironmentWhat is really happening ...   Ocho años en espiral  Pfizer despide a 800 investigadore...
A Global Collaborative Environment In 2011…                                          Paul Isherwood                       ...
A Global Collaborative EnvironmentThe number of alliances confirms the new scenario                                    Mer...
A Global Collaborative EnvironmentThe number of alliances confirms the new scenario                                       ...
A Global Collaborative Environment                            Distribution by Stage at Signing for Alliances              ...
A Global Collaborative EnvironmentExternal origin of R&D projects in a sample of the Top-25 companies            Ranking  ...
A Global Collaborative EnvironmentCollaborative R&D: not a brand new concept...            20%                            ...
A Global Collaborative Environment                                   .  Forbes Magazine August 22, 2011            Rallyin...
A Global Collaborative Environment  Mind the gap…   Bridge companies                                                      ...
A Global Collaborative EnvironmentDrug development scorecard: Jan-06 to Dec-07        Pharma are still necessary…       No...
A Global Collaborative Environment         Market                                      Technology                  What is...
A Global Collaborative Environment         Market                                      Technology                  What is...
A Global EnvironmentWhat to do...                                                      To increase Corporate efficiency:  ...
The required evolutionThe regulatory (r)evolution: towards the Virtual Physiological Human                                ...
The required evolutionThe regulatory (r)evolution: towards the Virtual Physiological Human        Santos Dumont Airplane  ...
The required evolutionThe regulatory (r)evolution: towards the Virtual Physiological Human 2000-2010The IUPS Physiome Proj...
The required evolutionThe regulatory (r)evolution: towards the Virtual Physiological Human  72 M euros del 7PM            ...
The required evolutionThe regulatory (r)evolution: towards the Virtual Physiological Human  La apuesta americana          ...
The required evolutionThe regulatory (r)evolution: towards the Virtual Physiological Human  ARGOS: La integraciónARGOS Pos...
The required evolutionThe regulatory (r)evolution: towards the Virtual Physiological Human                                ...
The required evolution  The Drug Develepment Process can dramatically change in 2020...                                  F...
The required evolution  The Drug Develepment Process can dramatically change in 2020...      First into Man    (Adaptive D...
The required evolutionThe goal is to re-shape the curve investment/return...Source: PWC                                   ...
Outline          A Global Collaborative          Environment          Collaborative Innovation @          Ferrer          ...
FerrerCollaborative Innovation @ Ferrer                                        Collaborative                              ...
FerrerCollaborative Innovation @ Ferrer                             Collaborative                                         ...
FerrerCollaborative Innovation @ Ferrer                                             Collaborative                         ...
FerrerCollaborative Innovation @ Ferrer                                              Collaborative                        ...
FerrerCollaborative Innovation @ Ferrer                                            Collaborative                          ...
FerrerCollaborative Innovation @ Ferrer                                                                 Collaborative     ...
FerrerWhat do we look for                                                                       Collaborative             ...
FerrerWhat do we look for                                                                                Collaborative    ...
FerrerWhat do we look for                                                                                                 ...
FerrerWhat do we look for                                              Collaborative                                      ...
FerrerWhat do we look for                                                         Collaborative                           ...
FerrerWhat do we look for                                                 Collaborative                                   ...
FerrerWhat do we look for                                                            Collaborative                        ...
FerrerWhat do we look for                                                                        Collaborative            ...
FerrerWhat do we look for                                                                   Collaborative                 ...
FerrerWhat do we look for                                                               Collaborative                     ...
FerrerWhat do we look for                                               Collaborative                                     ...
FerrerWhat do we look for                                                                          Collaborative          ...
FerrerWhat do we look for                                                                        Collaborative            ...
FerrerWhat do we look for                                                            Collaborative                        ...
FerrerWhat do we look for                                                            Collaborative                        ...
FerrerWhat do we look for                                          Collaborative                                          ...
“Drawing the       future     throughCollaborative Innovation”          Barcelona 14/09/2011
Gràcies!           Barcelona 14/09/2011
Barcelona 14/09/2011
Upcoming SlideShare
Loading in...5
×

Ag fernández collab_innov_140911

401

Published on

Published in: Technology, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
401
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Ag fernández collab_innov_140911

  1. 1. Collaborative InnovationThe role of the Academy and the Pharma IndustryJoining our Efforts, Sharing our Future Innovation in Biotechnology Business Development & Licensing International Division Barcelona 14/09/2011 CONFIDENTIAL September 14, 2011 agfernandez@ferrergrupo.com
  2. 2. Outline A Global Collaborative Environment Collaborative Innovation @ Ferrer Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  3. 3. A Global EnvironmentTrends in Biopharma Industry. The future has arrived. The stocks of some of the industrys biggest players, including Pfizer and Merck, are down 40% from a decade ago. A dramatic lost of efficiency and competitiveness has been experienced by the pharma companies over the last 15 years The industry has cut 300,000 jobs in the last 10 years. Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  4. 4. A Global EnvironmentWhat to do... To increase Corporate efficiency: Promote M&A, … A dramatic lost of efficiency and competitiveness has been To increase R&D efficiency: experienced by the pharma Change the research model companies over the last 15 years To achieve system sustainability: Evolve the regulatory model Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  5. 5. A Global Environment And M&A arrived... PHARMACIA PFIZER INC. UPJOHN WARNERT-LAMBERT PHARMACIA-UPJOHN AMERICAN CYANAMIDMONSANTO PFIZER INC. WYETH PHARMACIA CORP. PFIZER PFIZER Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  6. 6. A Global Environment SANOFI RHONE-POULENC R STERLING W FISONS SANOFI-WINTHROP RHONE-POULENC R SYNTHELABOSANOFI-SYNTHELABO SANOFI-AVENTIS AVENTIS HOECHST- HOECHST HMR MARION MERRELL DOW MARION MERRELL DOW ROUSSEL-UCLAF Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  7. 7. A Global EnvironmentFocus on reducing generic-induced erosion of revenues... Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  8. 8. A Global EnvironmentBut… are M&A solving the problem?What about the announced synergies? % world market Consolidation effects Dec-98 Dec-03 Dec-08 PFIZER 9.0 10.1 7.8 SANOFI- 5.8 5.4 5.8 AVENTIS GSK 7.2 6.6 7.0 Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  9. 9. A Global EnvironmentWhat to do... To increase Corporate efficiency: Promote M&A, … A dramatic lost of efficiency and competitiveness has been To increase R&D efficiency: experienced by the pharma Change the research model companies over the last 15 years To achieve system sustainability: Evolve the regulatory model Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  10. 10. A Global Collaborative Environment In 1996… Jürgen Drews Hoffmann-La Roche International Research Division, Former President Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  11. 11. A Global Collaborative Environment 1975 1985 1995 2005 2015 CLIN CLIN CLIN CLIN CLIN DEVELOP DEVELOP DEVELOP DEVELOP DEVELOP DISCOV DISCOV DISCOV DISCOV DISCOVERY BIOTECH INDUSTRY BIOTECH DISCOVERY ACADEMIA ACAD ACAD ACAD Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  12. 12. A Global Collaborative Environment 1975 1985 1995 2005 2015… CLIN CLIN CLIN CLIN CLIN DEVELOP DEVELOP DEVELOP DEVELOP Increasingly fragmented value chain DEVELOP DISCOV DISCOV DISCOV DISCOV DISCOVERY BIOTECH INDUSTRY BIOTECH DISCOVERY ACAD ACAD ACAD Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  13. 13. A Global Collaborative EnvironmentWhat is really happening ... Ocho años en espiral  Pfizer despide a 800 investigadores y cierra 6 centros de I+D de un total de 20 (2009).  J&J anuncia disminución inversión en Discovery (2008).  Procter & Gamble anuncia el cierre de sus centros dedicados al Discovery farmacéutico (2006).  Wyeth congela sus inversiones en Discovery (2005).  GSK declara que el 50 % de su pipeline clínico se ha obtenido mediante licensing in (2004).  > 60% del pipeline de Novartis ha sido descubierto extramuros (2003). Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  14. 14. A Global Collaborative Environment In 2011… Paul Isherwood GlaxoSmithKline Director of Innovation Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  15. 15. A Global Collaborative EnvironmentThe number of alliances confirms the new scenario Merck: More than 300 alliances in 6 years 500% increase in 7 years 60 Alliances / year 50 40 30 20 10 0 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  16. 16. A Global Collaborative EnvironmentThe number of alliances confirms the new scenario Announced Deals (2005-2009) 160 140 Deals 120 100 80 60 40 20 0 Source: Deloitte Recap LLC Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  17. 17. A Global Collaborative Environment Distribution by Stage at Signing for Alliances Early Mid Late 100%Late Stage 90% 30% 31% 33%Approved 270 80% 34% 43%Phase III 197 70%Phase II 151 13% 60% 17% 14% 20%Mid Stage 50% 19%Phase I 107 40%Preclinical 191 30% 58% 52% 52% 46%Early stage 20% 38%Lead molec. 76 10%Discovery 832 0% 2005 2006 2007 2008 2009 Source: Deloitte Recap LLC Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  18. 18. A Global Collaborative EnvironmentExternal origin of R&D projects in a sample of the Top-25 companies Ranking Projects of R&D projects position Company External origin (2010) (2010) (%) 1 Pfizer 304 26 3 Merck & Co 249 41 7 Sanofi-Aventis 137 46 12 Takeda 90 50 18 Boehringer Ing 53 38 19 Merck KGaA 53 64 21 Kyowa Hakko 52 52 Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  19. 19. A Global Collaborative EnvironmentCollaborative R&D: not a brand new concept... 20% During the late 19th and the early part of the 20th, practically all research 15% had been conducted outsourced 10% 5% Golden age of R&D corporate labs 0% 1900 1920 1940 1960 1980 2000 Source: EIRMA Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  20. 20. A Global Collaborative Environment . Forbes Magazine August 22, 2011 Rallying Pharmas Rebels Munos Laws 1. Regain the trust of physicians, regulators and payers. 2. Stop chasing blockbusters, which help lots of people a little bit, and start chasing breakthroughs, which help patients a lot. Bernard Munos has a 3. Do what works. Stop trying to manage drug discovery radical idea to save the with Six Sigma processes. drug industry: 4. Lower costs with collaborative research. 5. Mitigate risk by developing lots of potential Take bigger risks, do breakthroughs, not by trying to develop projects that collaborative research seem low-risk. History says the risk is never low. and cut R&D.. 6. Dont move anything into human trials unless it is a potential breakthrough. 7. Cut research and development. “Is there a less bureaucratic and cheaper way to invent new medicines? Former Big Pharma bigwigs say… yes! Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  21. 21. A Global Collaborative Environment Mind the gap… Bridge companies New York University University of Pennsylvania University of Florida Columbia University Memorial Sloan-Kettering  BIOPONTIS (USA) University of North Carolina University of Virginia A brand new company covering 7 prestigious east- coast institutions & recruiting pharma companies.  JANUS Developments (EU) A 2-years operating company mainly covering the Spanish public institutions. Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  22. 22. A Global Collaborative EnvironmentDrug development scorecard: Jan-06 to Dec-07 Pharma are still necessary… Novel drugs (excluding me-too) FDA approvals Phase III failures Biotech 9 42 Biotech-Pharma alliances 5 5 Pharma 16 4 Source: EA Czerepak & S Ryser (2008). Drug approvals and failures: implications for alliances. Nat Rev Drug Discov 7: 197-8. Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  23. 23. A Global Collaborative Environment Market Technology What is What is needed? possible? Here is where innovation What fits our strategy? happens Business Model Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  24. 24. A Global Collaborative Environment Market Technology What is What is needed? possible? Collaborative Innovation What fits our strategy? improves the room and the likelihood Business Model Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  25. 25. A Global EnvironmentWhat to do... To increase Corporate efficiency: Promote M&A, … A dramatic lost of efficiency and competitiveness has been To increase R&D efficiency: experienced by the pharma Change the research model companies over the last 15 years To achieve system sustainability: Evolve the regulatory model Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  26. 26. The required evolutionThe regulatory (r)evolution: towards the Virtual Physiological Human Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  27. 27. The required evolutionThe regulatory (r)evolution: towards the Virtual Physiological Human Santos Dumont Airplane Airbus A-380 Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  28. 28. The required evolutionThe regulatory (r)evolution: towards the Virtual Physiological Human 2000-2010The IUPS Physiome Project is a worldwide effort todefine the physiome through the development ofdatabases and models which will facilitate theunderstanding of the integrative function of cells,organs, and organisms. The project is focused oncompiling and providing a central repository ofdatabases, linking experimental information andcomputational models from many laboratories into asingle, self-consistent framework. Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  29. 29. The required evolutionThe regulatory (r)evolution: towards the Virtual Physiological Human 72 M euros del 7PM Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  30. 30. The required evolutionThe regulatory (r)evolution: towards the Virtual Physiological Human La apuesta americana Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  31. 31. The required evolutionThe regulatory (r)evolution: towards the Virtual Physiological Human ARGOS: La integraciónARGOS Position paper on VPH ResearchThe vision of integrative biomedical science, shared by a number of distinctly innovative newapproaches including systems biology, multiscale modeling, and the physiome, will becomepractically possible only when an entirely new framework of methods and technologies has beendeveloped for investigating organisms as single systems. In Europe, this framework has been namedthe Virtual Physiological Human. In the USA, while this particular name is not typically in use, thesame concept has been expressed repeatedly in a variety of publications and venues.Modeling and simulation of human physiology and diseases with a focus on the VirtualPhysiological Human (VPH) and the use of such solutions to support the diagnosis and treatment ofrare diseases. Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  32. 32. The required evolutionThe regulatory (r)evolution: towards the Virtual Physiological Human The current process Hit ID/ Synthesis Testing Testing Initial Design of screening Target ID molecule of of Molecule Molecule testing in molecule in vitro in vivo man molecule In silico Lab Clinical The process after VPH Testing Synthesis Initial Design of Target ID treatment of of testing in treatment treatment man Primary Pharmacol. Wide-ligand profiling ADME properties Pharmac. ScienceSource: PWC Toxicology Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  33. 33. The required evolution The Drug Develepment Process can dramatically change in 2020... First into Man Limited (Adaptive Design) 20-100 patients Clinical useSource: PWC Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  34. 34. The required evolution The Drug Develepment Process can dramatically change in 2020... First into Man (Adaptive Design) 20-100 patientsSource: PWC Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  35. 35. The required evolutionThe goal is to re-shape the curve investment/return...Source: PWC Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  36. 36. Outline A Global Collaborative Environment Collaborative Innovation @ Ferrer Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  37. 37. FerrerCollaborative Innovation @ Ferrer Collaborative Innovation Recently, Ferrer has created the Area of Innovation in Biotechnology Ferrer  Focused on expanding Collaborative Research.  Identifying, incorporating and (co-)managingCollaborative projects originated outside the company.Innovation Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  38. 38. FerrerCollaborative Innovation @ Ferrer Collaborative Innovation We like to consider the world as our lab, and therefore… Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  39. 39. FerrerCollaborative Innovation @ Ferrer Collaborative Innovation We like to promote ALLIANCES… as a way of achieving critical mass… as a way of optimizing resources… as a way of lowering risk… as part of our own culture… Open Innovation @ Ferrer Research Development FERRER BIOTECH ACADEMY Time Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  40. 40. FerrerCollaborative Innovation @ Ferrer Collaborative Innovation Connect Routine activities  Classical Scouting.  Personal Networking.  Domestic & International events.  Active communication/spreading of our policy/interests (internal & external). Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  41. 41. FerrerCollaborative Innovation @ Ferrer Collaborative Innovation Connect Special initiatives Ferrer ATTGCGCCATGCGT Initiative for GCFINESTCGACGA Networking and TTAGCCATAGGCTA Excellence in Health Sciences and Therapeutics Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  42. 42. FerrerCollaborative Innovation @ Ferrer Collaborative Innovation Connect Special initiatives  A network of Excellence (by invitation only):  Composed by emerging and brilliant middle age bioscientists and clinicians. ATTGCGCCATGCGT  Extend coverage of translational medicine. GCFINESTCGACGA  A think tank to help in:  Prospective TTAGCCATAGGCTA  Strategy design.  Emerging opportunities.  Avoiding /anticipating pitfalls and no-ways.  A virtual community with an attractive intranet (web based) platform & blog .  Annual Presential Meeting. Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  43. 43. FerrerWhat do we look for Collaborative Innovation Projects yielding high added value products Next slides will define our…  Development Segment Target (Entry Point)  Main Strategic Areas  Preferred Technological Platforms but, we do also like OPPORTUNITIES Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  44. 44. FerrerWhat do we look for Collaborative Innovation Why do we need high added valued products? Regulatory agencies HTA Compound A is safe? Is effective?  Which one is the most effective? has it a suitable benefit risk ratio ? Which one exhibits the best healtheconomics profile? Which one Compound B is safe? Is effective? solves an unmeet medical need? has it a suitable benefit risk ratio ? Compound A approved Compound A is reimbursed AND OR Compound B approved Compound B is reimbursed Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  45. 45. FerrerWhat do we look for Collaborative InnovationENTRY POINT Years Industry averages 0 2 4 6 8 10 12 Cost * Time** PoS*** 37 D Target ID 37 I S Assay Development 28 C O HTS Screening 25 2.7 V % Hit To Lead 19 E R Lead Optimization 9 Y pPoC / Preclinical Dev 5 D E Phase I 3 V E Phase IIA / cPoC 2 L O Phase IIB 1.5 P M Phase III 1.1 E N Registration 1 T * MUSD ** Years Source: Gaviragui, 2011 *** Probability of Success Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  46. 46. FerrerWhat do we look for Collaborative Innovation Main Strategic Areas Cardiovascular CNS Gastrointestinal Dermatology Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  47. 47. FerrerWhat do we look for Collaborative Innovation Other areas of interest Oncology Ophtalmology Oncology support Anti-infectives Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  48. 48. FerrerWhat do we look for Collaborative Innovation Technological platforms: their pivotal importance Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  49. 49. FerrerWhat do we look for Collaborative Innovation Preferred technological platforms Regenerative Medicine  Ophtalmology  CNS (stroke…)  Specific opportunities  Technology scouting:  Reprogramming evolution  New biomaterials Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  50. 50. FerrerWhat do we look for Collaborative Innovation Preferred technological platforms New Drug Therapies: antibodies  New Generation Antibodies  LMW: Nanobodies  Bispecific – Trispecific antibodies Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  51. 51. FerrerWhat do we look for Collaborative Innovation Preferred technological platforms New Drug Therapies: New GPCRs modulators  Deorphanised GPCRs: focus in CNS  “Valued” Oligomeric GPCRs: focus in CNS  PAM, NAM & bitopics discovery technologies or opportunities Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  52. 52. FerrerWhat do we look for Collaborative Innovation Preferred technological platforms Gene Therapies  Plasmids  Very specific/singular opportunities in:  siRNA  Antisense  Oncolytic viruses Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  53. 53. FerrerWhat do we look for Collaborative Innovation Preferred technological platforms Repositioning  Strong IP status  Fast development Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  54. 54. FerrerWhat do we look for Collaborative Innovation Preferred technological platforms New Protein Production or Delivery Technologies applied to  Rare diseases  Protein deficiency  Very specific opportunities in therapeutic vaccines  Advanced stage of development Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  55. 55. FerrerWhat do we look for Collaborative Innovation Preferred technological platforms New Frontiers in Predictive Medicine  Theranostics  Epigenetics  Metabolomics  Transcriptomics  Non-image based CNS diagnostic tools Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  56. 56. FerrerWhat do we look for Collaborative Innovation Theranos/ Reg Med New Drug Gene Th. Reprof. T. Vacc. Diagnos. …and opportunities Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  57. 57. FerrerWhat do we look for Collaborative Innovation Theranos/ Reg Med New Drug Gene Th. Reprof. T. Vacc. Diagnos. …and opportunities Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  58. 58. FerrerWhat do we look for Collaborative Innovation Pipeline: an idealized 3D representation Phase 3 Phase 2 Phase 1 Precl. Dev. Candidate Hit to Lead Discovery Barcelona 14/09/2011 © Ferrer, 2011 agfernandez@ferrergrupo.com
  59. 59. “Drawing the future throughCollaborative Innovation” Barcelona 14/09/2011
  60. 60. Gràcies! Barcelona 14/09/2011
  61. 61. Barcelona 14/09/2011
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×